An Alzheimer's drug developed by Swiss company Roche could not be proven in clinical trials to slow the progression of dementia, the pharmaceutical giant said Monday.
In a statement, Roche said the drug, gantenerumab, "did not meet their primary endpoint of slowing clinical decline" in a pair of studies conducted by the company. The identical studies, which were conducted with patients over the course of two years, were held in an effort to prove that gantenerumab could preserve certain functions in early Alzheimer's patients, including problem-solving skills, memory, and judgment.
While the trials were successful in showing a slight rate of decline, neither of them were described by Roche as being "statistically significant."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"So many of our families have been directly affected by Alzheimer's, so this news is very disappointing to deliver," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and head of global product development. "We are profoundly grateful to the study participants, their care partners, and study sites for their contributions to this research."
The faults of the studies now leave a trio of Roche's competitors, Biogen, Eisai, and Eli Lilly as the leaders in the medical community's effort to get an Alzheimer's treatment on the market.
The results saw economic ramifications as well, and Reuters reported that financial services firm Credit Suisse called the studies an "unequivocal" failure. Shares of Roche fell to their lowest in seven weeks, Reuters noted, with shares of Biogen and Eli Lilly rising 3.8 percent and 2.3 percent, respectively.
-
To the point: the gender divide over exclamation marksTalking Point 'Men harbouring urges to be more exclamative' can finally take a breath – this is what using the punctuation really conveys
-
Macbeth: a ‘genuinely scary’ productionThe Week Recommends Daniel Raggett’s nightmarish modern-day staging is set in a boozer in gangland Glasgow
-
The Mastermind: Josh O’Connor stars in unconventional art heist movieThe Week Recommends Kelly Reichardt cements her status as the ‘queen of slow cinema’ with her latest film
-
Peanut allergies have plummeted in childrenUnder the radar Early introduction could be an effective prevention method
-
Can TrumpRx really lower drug prices?Today’s Big Question Pfizer’s deal with Trump sent drugmaker stocks higher
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
The UK’s opioid crisis: why the stats don’t add upThe Explainer A new report has revealed that the UK’s total of opioid-related deaths could be much greater than official figures show
-
Human evolution may be responsible for autism ratesUnder the radar Neurodiversity and a complex brain may go hand in hand
-
Scientists are speeding up evolutionUnder the radar Proteins can evolve in minutes
-
A new subtype of diabetes was found and it may require different treatmentUnder the radar It is prevalent in Black Africans and Americans
